Respond Summary

Think about your direct supervisor. Apply the five rights of communication to that relationship. Tell us what you learned about how you should be communicating with your supervisor. Do you have to change anything in your approach?

• The Right Person –QI Manager
• The Right Route –She prefers scheduled meetings for larger discussions and emails for smaller scale items or just FYI. She doesn’t particularly like “pop in the office” when you want communication.
• The Right Time –As soon as a concern is identified.
• The Right Dose –The overall concern with details that particularly pertain to QI
• The Right Information –The issues identified, goals, budget, objectives, key stakeholders and a timeline

The areas I have identified that I need to change is the route I deliver information to her. My personality type is friendly and I love to stop by her office just to say “hi” or tell her something but have realized her schedule is very full and I may be interrupting her. Another thing I have identified is the right information. Even though she is the manager of QI, if she gives us a project, she doesn’t want to know all the little details. She trust us and is available if we have questions regarding the project but she doesn’t need or want to know every detail about the project.

This TD has helped me identify areas I’m doing okay in and areas I need to improve on as an executive leader. Overall, I feel that I should work on the 5 rights of communication to become a more proficient executive leader. I will use this format moving forward in order to hardwire the concept so that I can be more proficient in communicating and leading,

Need an argumentative essay on Molecular Neuro-degeneration. Needs to be 8 pages. Please no plagiarism.

It is evident that no drug has been discovered that could to completely protect neurons. there are two possible approaches to that may come up with the treatment of AD. One approach involves treatment which prevents the onset of the disease through curbing the primary targets and reducing the subsequent pathologies of the AD. This way, it becomes possible to slow the disease progression and hence prevention to the development of AD (Vradenburg 2013).

The second approach involves the symptomatic treatment. an approach whereby the primary and tertiary symptoms of the AD are declined. Through this approach, reflection to the current state of treatment including the usual treatment the cognitive impairment, the decline in global function, deteriorating performance of activities of daily living and behavioral change ( Perry 2013).

When searching for the appropriate treatment strategies, scientists concentrate on the severity of the disease and also the specificity of each individual. Currently the available therapeutic agents are the main target to specific symptoms of the AD. the agents such as cholinesterase inhibitors involved in the enhancement of cholinergic neurotransmission and also the inhibiting of acetylcholine degradation within the synapse are the Alzheimer’s disease main treatment (Vradenburg 2013).

Going by the report on the role of the involvement of PI3 kinase signaling in Aβ-induced memory loss in Drosophila, the PI3K-Akt-mTOR pathway regulation in Aβ oligomer neuronal cell cycle process and Amyloid-b Interruption of the PI3K-Akt-mTOR signaling pathway involvement in brain-derived neurotrophic factor-induced arc expression in rat scientists can improve theirs unleash a further superior drug to completely heal the Alzheimer’s disease (Perry 2013).

One of the hindrances to the progress of other researchers on AD have been due to the fact that most drugs developed show general success in animal specimens but when testing them to human beings, they become less responsive, Therefore, it is safe to say that this project is still in its infancy and further studies have to be carried out but in the long run a solution will be arrived upon.